JAK/STAT blockade reverses the malignant phenotype of Hodgkin and Reed-Sternberg cells
| Autor: | Sara, Fernández, Jose L, Solórzano, Eva, Díaz, Victoria, Menéndez, Lorena, Maestre, Sara, Palacios, Mar, López, Argentina Colmenero, Velázquez, Mónica, Estévez, Carlos, Montalban, Angel, Martinez-Ramirez, Giovanna, Roncador, Juan F, García |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Blood Advances. |
| ISSN: | 2473-9537 2473-9529 |
| DOI: | 10.1182/bloodadvances.2021006336 |
| Popis: | Constitutive activation of the JAK/STAT pathway is a common phenomenon in classic Hodgkin lymphoma (cHL). The clinical potential of anti-JAK/STAT therapy is being explored in early-stage clinical trials. Notwithstanding, very little information is available about the complex biological consequences of this blockade. Here we investigated the effects of JAK/STAT pharmacological inhibition on cHL cell models using ruxolitinib, a JAK 1/2 inhibitor that induces apoptosis by concentration- and time-dependent mechanisms. An unbiased whole-transcriptome approach identified expression of the anti-GCSF receptor (CSF3R) as a potential surrogate biomarker of JAK/STAT overactivation. Additionally, longitudinal gene expression analyses provided further mechanistic information about pertinent biological pathways involved, including 37 gene pathways distributed in three main clusters: one was characterized by upregulation of the G2/M checkpoint and MHC-related clusters; two additional clusters showed a progressive down regulation of the tumor-promoting inflammation signatures: JAK/STAT and IL1/IL4/IL13/IL17. Together, our results confirm the therapeutic potential of JAK/STAT inhibitors in cHL, identify CSF3R as a new biomarker, and provide supporting genetic data and mechanistic understanding. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|